[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:b-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":320},"B-Cell Non-Hodgkin Lymphoma",62,48,[8,16,23,29,35,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,192,198,204,210,216,222,228,234,240,246,251,257,263,269,275,281,286,292,298,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07220616","A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.664150Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05685173","A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas",[20],"Phase 1","2026-08-26T02:16:54.876240Z","2026-06-18T12:24:02.495363Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05463263","A Phase 1\u002F2 Study of STP938 for Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:29.494912Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06343311","T-Cell Therapy (EB103) in Adults With Relapsed\u002FRefractory B-Cell Non-Hodgkin's Lymphoma (NHL)",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:29.473046Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06954805","Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)",[39],"Phase 2","2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.355601Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06544265","SynKIR-310 for Relapsed\u002FRefractory B-NHL",[20],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:28.803898Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06218602","Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.",[39],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.741195Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04544592","UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.281463Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04989803","Study of KITE-363 or KITE-753 in Participants With Relapsed and\u002For Refractory B-cell Lymphoma",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.221005Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05607420","Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:28.207321Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06420089","CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)",[20],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.338830Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05801913","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.275760Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT07284433","Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19\u002FCD20, in Patients With Relapsed or Refractory B-Cell Malignancies",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:26.758756Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05272384","Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma",[20],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.137336Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05370430","BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.804231Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05681195","Zanubrutinib With Pemetrexed to Treat Relapsed\u002FRefractory Primary and Secondary Central Nervous System (CNS) Lymphomas",[39],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.471359Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.592999Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[39],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.476441Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT02693535","TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",[39],"2026-08-26T02:18:04.640417Z","2026-05-05T02:43:26.719459Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05389423","Pomalidomide and Dose-Adjusted EPOCH +\u002F- Rituximab for HIV-Associated Lymphomas",[20],"2026-08-26T02:19:23.493898Z","2026-05-05T02:35:31.746900Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT04792502","Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",[39],"2026-08-26T02:15:03.757872Z","2026-04-29T02:57:57.106355Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05432635","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",[20],"2026-08-26T02:16:07.529922Z","2026-04-29T02:57:57.084734Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[20],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[39],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.737268Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",[20],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.733199Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT03017820","A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",[20],"2026-08-26T02:19:05.360997Z","2026-06-16T05:54:07.906191Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[20],"2026-08-26T02:16:39.977107Z","2026-05-13T02:55:06.706937Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06564038","A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",[12],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.532592Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06484920","A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL",[39],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.397408Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[20],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06285825","A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia",[39],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.728703Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[20],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",[12],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.622855Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT06191887","B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",[20],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.173828Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[39],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":244,"content_modified":250},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[20],"2026-05-05T02:35:31.752653Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05436418","The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation",[12],"2026-08-26T02:17:18.747857Z","2026-05-05T02:35:31.635324Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT07652580","Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma",[],"2026-08-26T02:16:16.995720Z","2026-06-17T19:21:16.684827Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT05865301","Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy",[],"2026-08-26T02:18:59.761994Z","2026-05-13T02:55:06.390506Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT07691606","A Study of ARC-02 in B-cell NHL",[20],"2026-08-26T02:18:42.501841Z","2026-07-19T19:36:05.152398Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.418667Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":136,"content_modified":285},"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-T Cells",[],"2026-05-13T02:55:06.122685Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT07609030","A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma",[],"2026-08-26T02:17:33.002248Z","2026-05-29T15:36:40.226551Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06052826","Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study",[39],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:28.883512Z",{"nct_id":299,"title":300,"phases":301,"status":302,"updated_at":303,"content_modified":304},"NCT07607925","A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:55.570428Z","2026-06-18T12:24:03.102890Z",{"nct_id":306,"title":307,"phases":308,"status":302,"updated_at":309,"content_modified":310},"NCT07335328","Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies",[20],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.110589Z",[312,316],{"biomarker":313,"count":314,"slug":315},"CD19 Gene",10,"cd19-gene",{"biomarker":317,"count":318,"slug":319},"MS4A1 Gene",6,"ms4a1-gene",[321,325,329,333,337,341,345,349,353,356,359,362,365,369,373,376,379,382,385,388,392,395,398,401],{"state":322,"count":323,"slug":324},"Texas",24,"texas",{"state":326,"count":327,"slug":328},"California",21,"california",{"state":330,"count":331,"slug":332},"New York",18,"new-york",{"state":334,"count":335,"slug":336},"Ohio",17,"ohio",{"state":338,"count":339,"slug":340},"Pennsylvania",15,"pennsylvania",{"state":342,"count":343,"slug":344},"Florida",13,"florida",{"state":346,"count":347,"slug":348},"Wisconsin",12,"wisconsin",{"state":350,"count":351,"slug":352},"New Jersey",11,"new-jersey",{"state":354,"count":314,"slug":355},"Maryland","maryland",{"state":357,"count":314,"slug":358},"North Carolina","north-carolina",{"state":360,"count":314,"slug":361},"Tennessee","tennessee",{"state":363,"count":314,"slug":364},"Washington","washington",{"state":366,"count":367,"slug":368},"Colorado",9,"colorado",{"state":370,"count":371,"slug":372},"Arizona",8,"arizona",{"state":374,"count":371,"slug":375},"Georgia","georgia",{"state":377,"count":371,"slug":378},"Illinois","illinois",{"state":380,"count":371,"slug":381},"Massachusetts","massachusetts",{"state":383,"count":371,"slug":384},"Minnesota","minnesota",{"state":386,"count":371,"slug":387},"Virginia","virginia",{"state":389,"count":390,"slug":391},"Kentucky",7,"kentucky",{"state":393,"count":390,"slug":394},"Utah","utah",{"state":396,"count":318,"slug":397},"Alabama","alabama",{"state":399,"count":318,"slug":400},"Oregon","oregon",{"state":402,"count":403,"slug":404},"Connecticut",5,"connecticut"]